Mirum Pharmaceuticals (MIRM) News Today $46.28 -0.78 (-1.66%) Closing price 04:00 PM EasternExtended Trading$46.26 -0.02 (-0.04%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from AnalystsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus rating of "Buy" by the eleven brokerages that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buMarch 25 at 4:40 AM | marketbeat.comMirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell CallMarch 24 at 6:01 PM | seekingalpha.comMaintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To LikeMarch 24 at 3:53 PM | seekingalpha.comRaymond James Financial Inc. Purchases New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Raymond James Financial Inc. acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 256,612 shares of the company's stock, vMarch 21, 2025 | marketbeat.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 7,879 Shares of StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 7,879 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the sale, the chief operating officer now owns 18,672 shares in the company, valued at approximately $825,489.12. This trade represents a 29.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.March 19, 2025 | marketbeat.comChristopher Peetz Sells 27,279 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares of the company's stock, valued at approximately $6,129,318.61. This trade represents a 16.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 19, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $2,554,826.10 in StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 57,606 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. The trade was a 92.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.March 19, 2025 | marketbeat.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 7,879 Shares of StockMarch 19, 2025 | insidertrades.comMirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up - Here's WhyMirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up - Should You Buy?March 18, 2025 | marketbeat.comBank of New York Mellon Corp Has $5.14 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Bank of New York Mellon Corp increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,328 shares of the company's stock aMarch 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires 109,585 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 162.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,96March 16, 2025 | marketbeat.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10, 2025 | businesswire.comAigen Investment Management LP Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Aigen Investment Management LP acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,742 shares of the company's stock, valueMarch 9, 2025 | marketbeat.comInsider Buying: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Purchases 1,335 Shares of StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) Director Patrick J. Heron acquired 1,335 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $45.57 per share, with a total value of $60,835.95. Following the completion of the purchase, the director now owns 163,643 shares in the company, valued at $7,457,211.51. This represents a 0.82 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 7, 2025 | marketbeat.comPatrick J. Heron Buys 1,335 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMarch 7, 2025 | insidertrades.comCandriam S.C.A. Sells 78,744 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Candriam S.C.A. trimmed its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 429,731 shares of the company's stock after selliMarch 7, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)March 3, 2025 | markets.businessinsider.comEquities Analysts Issue Forecasts for MIRM FY2025 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the companyMarch 3, 2025 | marketbeat.comEquities Analysts Offer Predictions for MIRM Q3 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Mirum Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar expects that the compaMarch 3, 2025 | marketbeat.comAnalyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year ReportMarch 1, 2025 | finance.yahoo.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC WainwrightHC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday.March 1, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings MissMirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% Following Weak EarningsFebruary 28, 2025 | marketbeat.comMirum Pharmaceuticals price target raised to $65 from $63 at Morgan StanleyFebruary 28, 2025 | markets.businessinsider.comRobert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock PriceRobert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday.February 28, 2025 | marketbeat.comMirum Pharmaceuticals price target raised to $55 from $50 at BairdFebruary 28, 2025 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)February 28, 2025 | markets.businessinsider.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by BrokeragesShares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have received a consensus recommendation of "Buy" from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy rating and one has assignFebruary 28, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPSMirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) released its earnings results on Wednesday. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%.February 27, 2025 | marketbeat.comPhocas Financial Corp. Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Phocas Financial Corp. trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 85.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,699 shares of the company'February 27, 2025 | marketbeat.comMirum Pharmaceuticals misses Q4 earnings, stock fallsFebruary 26, 2025 | in.investing.comMirum Pharmaceuticals reports FY24 EPS ($1.85), consensus ($1.42)February 26, 2025 | markets.businessinsider.comMirum Pharmaceuticals sees FY25 product sales of $420M-$435M vs. $336.4M in FY24February 26, 2025 | markets.businessinsider.comMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateFebruary 26, 2025 | finance.yahoo.comMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateFebruary 26, 2025 | businesswire.comMirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to AnalystsFebruary 26, 2025 | msn.comAllspring Global Investments Holdings LLC Acquires New Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Allspring Global Investments Holdings LLC purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,981 shares of the company's stock, valuFebruary 25, 2025 | marketbeat.comMirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)February 24, 2025 | finance.yahoo.comDeal pays off for drugmaker with approval for rare cholesterol-related disease treatmentFebruary 24, 2025 | bizjournals.comMirum Pharmaceuticals announces FDA approval for Ctexli tabletsFebruary 24, 2025 | markets.businessinsider.comHealthInvest Partners AB Has $4.81 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)HealthInvest Partners AB decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,692 shares of the compFebruary 24, 2025 | marketbeat.comFDA approves Mirum treatment for cerebrotendinous xanthomatosisFebruary 21, 2025 | markets.businessinsider.comUS FDA approves Mirum Pharma's genetic disorder drugFebruary 21, 2025 | reuters.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Here's WhyMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High - Should You Buy?February 20, 2025 | marketbeat.comMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025February 19, 2025 | businesswire.comMirum Pharmaceuticals (MIRM) to Release Quarterly Earnings on WednesdayMirum Pharmaceuticals (NASDAQ:MIRM) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comEmpowered Funds LLC Purchases Shares of 33,266 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Empowered Funds LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,266 shares of the company's stoFebruary 17, 2025 | marketbeat.comMirum PharmaceuticalsFebruary 16, 2025 | forbes.comSG Americas Securities LLC Has $289,000 Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)SG Americas Securities LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 66.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the companyFebruary 6, 2025 | marketbeat.comMirum Pharmaceuticals president sells $126,680 in stockFebruary 5, 2025 | msn.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of StockFebruary 5, 2025 | insidertrades.com Remove Ads Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRM Media Mentions By Week MIRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼1.330.89▲Average Medical News Sentiment MIRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼84▲MIRM Articles Average Week Remove Ads Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today BridgeBio Pharma News Today Lantheus News Today TG Therapeutics News Today Legend Biotech News Today Axsome Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
